Liqiang Wei

机构：Beijing Tongren Hospital, Capital Medical University · ORCID：0000-0003-1465-2168

发表论文 30 篇 · 总被引 171 次 · h-index 7

代表论文

• First-line sintilimab with pegaspargase, gemcitabine, and oxaliplatin in advanced extranodal natural killer/T cell lymphoma (SPIRIT): a multicentre, single-arm, phase 2 trial (2024 · The Lancet Haematology · 被引 33)
• LncRNA BCYRN1-induced autophagy enhances asparaginase resistance in extranodal NK/T-cell lymphoma (2020 · Theranostics · 被引 32)
• Efficacy and safety of sirolimus in the treatment of blue rubber bleb naevus syndrome in paediatric patients (2019 · Clinical and Experimental Dermatology · 被引 21)
• Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center (2017 · International Journal of Hematology · 被引 18)
• Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis (2020 · Journal of Cancer Research and Clinical Oncology · 被引 17)
• Prediction of the response of ocular adnexal lymphoma to chemotherapy using combined pretreatment dynamic contrast-enhanced and diffusion-weighted MRI (2016 · Acta Radiologica · 被引 12)